Clearmind Medicine Inc (CMND)

Jun 29, 2026, 7:55 AM EDT - 5 days ago

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength

2026-06-22T13:23:09.000Z - 12 days ago

Clearmind completes treatment for all participants in Part A of CMND-100 trial

Jun 22, 2026, 8:07 AM EDT - 12 days ago

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

2026-06-18T12:10:06.000Z - 16 days ago

Clearmind Medicine granted U.S. patent for Binge Behavior Regulators

Jun 18, 2026, 7:55 AM EDT - 16 days ago

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

2026-06-16T11:45:08.000Z - 18 days ago

Clearmind Medicine completes dosing for four cohorts of CMND-100 trial

Jun 16, 2026, 7:32 AM EDT - 18 days ago

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Jun 15, 2026, 7:00 AM EDT - 19 days ago

Clearmind Medicine Quarterly report: Q2 2026

Jun 5, 2026, 7:32 AM EDT - 4 weeks ago

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

2026-05-29T13:48:45.000Z - 5 weeks ago

Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan

May 29, 2026, 8:32 AM EDT - 5 weeks ago

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

2026-05-26T14:54:27.000Z - 5 weeks ago

Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial

May 26, 2026, 8:25 AM EDT - 5 weeks ago

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

2026-05-20T23:55:09.000Z - 6 weeks ago

Clearmind Medicine Inc trading halted, news pending

2026-05-19T10:10:36.000Z - 6 weeks ago

Clearmind Medicine announces 1-for-10 reverse share split

May 19, 2026, 6:00 AM EDT - 6 weeks ago

Clearmind Medicine Announces 1-for-10 Reverse Share Split

2026-05-18T13:00:08.000Z - 6 weeks ago

Clearmind Medicine signs new research agreement with Yissum Research Development

May 18, 2026, 8:42 AM EDT - 6 weeks ago

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

May 15, 2026, 8:35 AM EDT - 7 weeks ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

May 12, 2026, 8:41 AM EDT - 7 weeks ago

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

May 11, 2026, 7:55 AM EDT - 7 weeks ago

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

2026-05-05T12:59:55.000Z - 2 months ago

Clearmind Medicine files European patent application for psychedelic compounds

May 5, 2026, 8:50 AM EDT - 2 months ago

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

2026-04-30T21:03:58.000Z - 2 months ago

Clearmind Medicine files to sell 22.63M common shares for holders

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Clearmind Medicine Registration statement: Registration filing

2026-04-27T11:48:40.000Z - 2 months ago

Clearmind announces evaluation of CMND-100 for breakthrough therapy designation

Apr 27, 2026, 7:41 AM EDT - 2 months ago

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Apr 20, 2026, 4:03 PM EDT - 2 months ago

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Apr 20, 2026, 7:15 AM EDT - 2 months ago

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Apr 15, 2026, 7:30 AM EDT - 2 months ago

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Apr 14, 2026, 7:32 AM EDT - 2 months ago

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 30, 2026, 8:32 AM EDT - 3 months ago

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Mar 27, 2026, 7:32 AM EDT - 3 months ago

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Mar 19, 2026, 8:45 AM EDT - 3 months ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 17, 2026, 9:15 AM EDT - 3 months ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 16, 2026, 7:30 AM EDT - 3 months ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 13, 2026, 7:45 AM EDT - 4 months ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 12, 2026, 5:00 PM EDT - 4 months ago

Clearmind Medicine Quarterly report: Q1 2026

Mar 11, 2026, 9:07 AM EDT - 4 months ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 7:30 AM EDT - 4 months ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 4 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Mar 4, 2026, 7:30 AM EST - 4 months ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Feb 19, 2026, 1:05 PM EST - 4 months ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 17, 2026, 7:00 AM EST - 4 months ago

Clearmind Medicine Registration statement: Registration Filing

Feb 9, 2026, 8:17 AM EST - 5 months ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 6, 2026, 7:55 AM EST - 5 months ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 3, 2026, 8:00 AM EST - 5 months ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Jan 20, 2026, 4:20 PM EST - 5 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 20, 2026, 7:00 AM EST - 5 months ago

Clearmind Medicine Annual report: Q4 2025

Jan 14, 2026, 8:55 AM EST - 6 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Dec 31, 2025, 9:10 AM EST - 6 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 24, 2025, 9:15 AM EST - 6 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 16, 2025, 8:45 AM EST - 7 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 12, 2025, 8:32 AM EST - 7 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 6:32 AM EST - 7 months ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 10, 2025, 4:15 PM EST - 7 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 5, 2025, 5:00 PM EST - 7 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 5, 2025, 7:00 AM EST - 7 months ago

Clearmind Medicine Registration statement: Registration Filing

Dec 2, 2025, 7:57 AM EST - 7 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 1, 2025, 8:56 AM EST - 7 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Nov 26, 2025, 7:00 AM EST - 7 months ago

Clearmind Medicine Registration statement: Registration Filing

Nov 25, 2025, 7:17 AM EST - 7 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 24, 2025, 8:51 AM EST - 7 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 20, 2025, 6:01 AM EST - 8 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 19, 2025, 8:30 AM EST - 8 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Nov 18, 2025, 8:56 AM EST - 8 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 17, 2025, 7:55 AM EST - 8 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 13, 2025, 8:54 AM EST - 8 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center